 | • レポートコード：MRC2303G011 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、2021年には4,253.30百万でドルあった世界の自己免疫疾患診断市場規模が、2027年には6,298.98百万ドルに及び、予測期間中（2022年-2027年）CAGR 6.8％で増加すると推測されています。本書では、自己免疫疾患診断の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患種類別（全身性自己免疫疾患、局部的自己免疫疾患）分析、診断別（抗核抗体検査、自己抗体検査、全血球計算（CBC）、C反応性タンパク（CRP）、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Abbott Laboratories、Biomerieux、Bio-rad Laboratories、Euroimmun AG、F. Hoffmann-la Roche、Inova Diagnostics Inc.などが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の自己免疫疾患診断市場規模：疾患種類別 - 全身性自己免疫疾患における市場規模 - 局部的自己免疫疾患における市場規模 ・世界の自己免疫疾患診断市場規模：診断別 - 抗核抗体検査における市場規模 - 自己抗体検査における市場規模 - 全血球計算（CBC）検査における市場規模 - C反応性タンパク（CRP）検査における市場規模 - その他検査における市場規模 ・世界の自己免疫疾患診断市場規模：地域別 - 北米の自己免疫疾患診断市場規模 アメリカの自己免疫疾患診断市場規模 カナダの自己免疫疾患診断市場規模 メキシコの自己免疫疾患診断市場規模 … - ヨーロッパの自己免疫疾患診断市場規模 ドイツの自己免疫疾患診断市場規模 イギリスの自己免疫疾患診断市場規模 フランスの自己免疫疾患診断市場規模 … - アジア太平洋の自己免疫疾患診断市場規模 中国の自己免疫疾患診断市場規模 日本の自己免疫疾患診断市場規模 インドの自己免疫疾患診断市場規模 … - 南米/中東の自己免疫疾患診断市場規模 ブラジルの自己免疫疾患診断市場規模 アルゼンチンの自己免疫疾患診断市場規模 サウジアラビアの自己免疫疾患診断市場規模 … ・競争状況 ・市場機会・将来動向 |
The autoimmune disease diagnostics market was valued at USD 4,253.30 million in 2021 and is projected to reach USD 6,298.98 million by 2027 registering a CAGR of nearly 6.8% during the forecast period (2022-2027).
The first wave of the COVID-19 pandemic has disrupted almost all areas of health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled “The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned,” published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020). Thus, Covid-19 has significant impact on the growth of the market.
The factors such as growing burden of autoimmune disease and rising awarness about the diagnosis of disease coupled with technical advancement is propelling the growth of the market.
The growing burden of the autoimmune diseases in the different parts of the world coupled with rising awareness about health and diseases creates need for the diagnostics for early detection of diseases and thus drives the growth of market. For instance, in November 2020, The Autoimmune Registry Inc, released its comprehensive list of autoimmune diseases in United States which includes over 150 diseases, 40 subtypes, and 60 synonyms. It also reported that there are about 15 to 30 million people in the United States suffer from autoimmune disease, making it one of the nation’s largest class of illness, often affecting women between 20 and 40 years old. Such high burden of disease is driving the growth of market. Also, the burden of different autoimmune diseases is growing largely in the countries around the world. For instance, the Atlas of Multiple Sclerosis Report, released in September 2020, stated that more than 2.8 million people currently are living with multiple sclerosis worldwide, including about 1 million in the United States. Such a high burden of disease is largely propelling the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, slow turnaround time of results and need for multiple diagnostic tests and high cost and reimbursement issues coupled with regulatory unceratinities may hamper the growth of the market.
Autoimmune Disease Diagnostics Market Trends
Rheumatoid Arthritis Segment is Expected to Hold a Major Market Share in the Autoimmune Disease Diagnostics Market
Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues within the joints. The disease predominantly affects elderly patients. The aging population and technological advancements are also major factors driving the growth of the segment.
Rheumatoid arthritis can be diagnosed using the erythrocyte sedimentation rate (ESR) test, C-reactive protein test, rheumatoid factor test, cyclic citrullinated peptide (CCP) antibodies, antinuclear antibodies (ANA) test, and other imaging.
Rheumatoid arthritis is a common disease diagnosed in the elderly population, with the rise in the burden of the geriatric population risk of rheumatoid arthritis increases and thus drives the growth of the market. For Instance, According to the World Population prospect, 2022, Globally, in 2022, there were 771 million people aged 65 years or over, and is projected to reach 994 million by 2030 and 1.6 billion by 2050.
The launch of new products by the market players is contributing to the growth of the market. For instance, in June 2022, PEPperPrint GmbH introduce a novel biomarker set for the early diagnosis of rheumatoid arthritis (RA) at the 13th International Congress on Autoimmunity held in Athens, Greece. Such innovation for the early diagnosis of the disease is expected to propel the growth of the market.
Thus, owing to the abovementioned factors, the market segment is expected to project considerable growth over the forecast period.
Asia-Pacific is the Fastest Growing Region in the Autoimmune Disease Diagnostics Market
Asia-Pacific is anticipated to exhibit extensive market growth over the forecast period, owing to the rising burden of autoimmune diseases and awareness of its diagnosis. Additionally, the strategic initiatives taken by the market players, increasing research, and developing healthcare infrastructure are also contributing to the growth of the market.
According to an article published by Janssen Asia Pacific, a division of Johnson & Johnson Pte. Ltd., titled “Immunological Diseases” published in June 2022, autoimmune, inflammatory, and pulmonary diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are on the rise in the Asia Pacific. The region already has the world’s highest burden of chronic obstructive pulmonary disease (COPD), as well as the highest prevalence of systemic lupus erythematosus (SLE) in China and Southeast Asia. Hence, this will likely create demand for diagnostics in the coming years.
Furthermore, according to the International Diabetes Federation, Diabetes Altas, 2021 Edition, in Australia, there are 14,900 people aged 0-19 years living with Type 1 diabetes in 2021, and the incidence of type 1 diabetes was 1,500 in 2021. Such a high burden of disease creates the need for the proper diagnosis and treatment and thus drives the growth of the market.
The strategic initiatives taken by the market players are also contributing to the growth of the market. For Instance, in June 2022, Avesthagen Limited entered into a four-year strategic alliance with Wipro Limited for commercializing its genetic testing portfolio in India. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders, and rare disease conditions. Such partnership is expected to boost the growth of the market.
Thus, owing to the abovementioned factors, the studied market is expected to project growth in the Asia-Pacific region.
Autoimmune Disease Diagnostics Market Competitor Analysis
The Autoimmune Disease Diagnostics Market is moderately competitive. The market comprises significant market players, and these players are focusing on R&D activities and effective growth strategies. Recently, a few diagnostic companies entered into strategic partnerships with hospitals. This trend is expected to continue over the next few years to meet the high volume of patient needs across different regions.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Autoimmune Diseases and Rising Public Awareness
4.2.2 Technological Advancements and Improved Laboratory Automation
4.3 Market Restraints
4.3.1 Slow Turnaround Time of Results and Need for Multiple Diagnostic Tests
4.3.2 High Cost and Reimbursement Issues Coupled with Regulatory Uncertainties
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Disease Type
5.1.1 Systemic Autoimmune Disease
5.1.1.1 Rheumatoid Arthritis
5.1.1.2 Psoriasis
5.1.1.3 Systemic Lupus Erythematosus (SLE)
5.1.1.4 Multiple Sclerosis
5.1.1.5 Other Systemic Autoimmune Diseases
5.1.2 Localized Autoimmune Disease
5.1.2.1 Inflammatory Bowel Disease
5.1.2.2 Type 1 Diabetes
5.1.2.3 Thyroid
5.1.2.4 Other Localized Autoimmune Diseases
5.2 By Diagnosis
5.2.1 Antinuclear Antibody Tests
5.2.2 Autoantibody Tests
5.2.3 Complete Blood Count (CBC)
5.2.4 C-reactive Protein (CRP)
5.2.5 Urinalysis
5.2.6 Others tests
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Biomerieux
6.1.3 Bio-rad Laboratories
6.1.4 Euroimmun AG
6.1.5 F. Hoffmann-la Roche
6.1.6 Inova Diagnostics Inc.
6.1.7 Myriad Genetics
6.1.8 Siemens Healthineers Inc.
6.1.9 Thermo Fisher Scientific
6.1.10 Trinity Biotech
6.1.11 Grifols, S.A.
6.1.12 Exagen Inc.
6.1.13 DIAsource ImmunoAssays SA
6.1.14 R-Biopharm AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
